Rapid seizure reduction
is possible.

In a landmark study with the RNS® System, patients saw a 62% median seizure reduction by 6 months.1

Take the quiz

to see if you may qualify for the RNS® System

Are you taking this survey for yourself or a loved one?


















If you are an existing RNS System patient, please direct questions to your physician or NeuroPace Customer Service at (866) 726.3876. Quiz submissions from existing RNS System patients are not accepted.

How old are you or your loved one? 
Do you or your loved one still have seizures even after trying 2 or more different anti-seizure medications?

Which of the following types of epilepsy have you or your loved one been diagnosed with?
Which of the following procedures have you or your loved one had (check all that apply)?
Are you being treated at one of the epilepsy centers below? If yes, please select that center. If your center is not on the list, please select “My center is not on the list.”
Filter
Search


It appears you may be a candidate!

To learn more about the RNS System and centers offering the RNS System, please include your phone number below and a Nurse Educator will contact you. 

If you do not provide your phone number, we will only email information about the RNS System to you.





By submitting this form, I give permission for NeuroPace to contact me via phone, email, or text message from time to time including regular informational emails. I understand that I can opt out of one or all communication methods at any time. NeuroPace will never sell my data or personal information, and I agree to the company's privacy policy.
The RNS System is not currently FDA approved for patients under the age of 18. However, we are currently enrolling patients in the RESPONSE Clinical Study to evaluate the RNS System in teens ages 12 through 17. To learn more, click "Done".

It appears that you may not be an appropriate candidate for the RNS® System at this time. It is FDA approved for people 18+ years of age with focal epilepsy who are still having seizures despite trying two or more medications. 
It appears your loved one may not be an appropriate candidate for the RNS® System at this time. It is FDA approved for people 18+ years of age with focal epilepsy who are still having seizures despite trying two or more medications. 

The RNS System is not currently FDA approved for patients with generalized epilepsy. However, we will be enrolling patients in the NAUTILUS Clinical Study to evaluate the RNS System in patients with primary generalized epilepsy. To learn more visit  https://www.neuropace.com/providers/clinical-research/



reCAPTCHA helps prevent automated form spam.
The submit button will be disabled until you complete the CAPTCHA.


Hear from Real Patients

What would you do with
fewer seizures every year?

Combined Patient Interviews
Combined Patient Interviews

See if you qualify for the RNS® System

Take the Quiz

What is the RNS® System?

The RNS System is a medical device that is FDA approved for the treatment of drug-resistant focal epilepsy (also called partial onset epilepsy). The RNS® System includes an implantable neurostimulator and small wires (called leads).

How does it work?

  1. 1

    Monitors

    It monitors brain activity continuously.

  2. 2

    Detects

    It is programmed to recognize a person’s unique seizure patterns, and automatically responds to prevent seizures before they start.

  3. 3

    Responds

    It records and reports EEG data to help doctors personalize patient care.

"With the RNS, I can go fishing, kayaking, drive, and operate equipment—with the confidence that I'm OK by myself."

-Tyler

Living seizure free
with the RNS® System*

*Every person’s seizures are different and individual results will vary.

See if you qualify for the RNS® System

Take the Quiz

  1. RNS System Post-approval Study Oral Presentation, American Academy of Neurology, April 2025, all outcomes are ITT, median seizure reduction is observed case data, seizure freedom at last follow-up is LOCF

Rx Only. The RNS® System is an adjunctive therapy for adults with refractory, partial onset seizures with no more than 2 epileptogenic foci. See important safety information at https://www.neuropace.com/safety/. Refer to the labeling for a description of the RNS® System and its components, indications for use, contraindications, warnings, cautions, adverse events and instructions for use. ©2025 NeuroPace, Inc. All rights reserved. NeuroPace and RNS are registered trademarks of NeuroPace, Inc., Mountain View, CA 94043.
NP 250065 Rev 1 / Rev. Date: 2025-05

Thank you for completing the quiz.
  • Safety Information
  • Legal
  • Privacy Policy
1-866-726-387624-hr Support Line

PATIENTS

  • Drug-Resistant Epilepsy
  • The RNS System
  • Hear from Patients
  • Is It Right for You?
  • Current Patients
  • Resources

PROVIDERS

  • Product
  • Clinical Benefits
  • Actionable Insights
  • Patient Selection
  • Education & Training
  • Resources

CORPORATE

  • In The News
  • Press Releases
  • Leadership
  • Careers
  • Contact Us
  • FCOI Procedure

  • PATIENTS

    Safety

  • PROVIDERS

    Legal

  • INVESTORS

    Privacy Policy

  • CORPORATE

1-866-726-3876 24-hr Support Line

© 2026 NeuroPace, Inc.

Step 1 of 7

14%
    The RNS System is for individuals 18 and older who have focal epilepsy and have tried two or more medications without finding seizure control.

  • Based on your answers, your patient might benefit from the RNS System.

    Get your profile and a list of questions to ask your doctor.

  • Unfortunately it appears your patient is not an appropriate candidate for the RNS® System at this time.

  • The RNS® System is intended for patients who have undergone diagnostic testing that localized no more than 2 epileptogenic foci.

    If your patient has not undergone diagnostic testing, search here to find a comprehensive epilepsy center that can evaluate your patient, including determining if the RNS System is right for them.

  • If you are interested in learning more about the RNS® System, you can have an RNS® System professional contact you by filling out the form below:

  • By filling out this form, you are agreeing to the terms of our privacy policy. This form is intended for US residents only.

    By clicking submit, you are agreeing to receive communications from NeuroPace. You can unsubscribe at any time.

    * Required fileds

Share your Story: Terms and conditions

By filling out the form and submitting your story (and/or photograph), you are agreeing to the following:

  1. NeuroPace may review the information and any photographs you provide for potential publication on our website.
  2. If NeuroPace decides to use your story, we will contact you and ask you to sign a release for a version of your story to be used on the NeuroPace website, Facebook, Instagram, Twitter and/or LinkedIn. Unless you sign the release, we will not publish the story, your name, or the photographs you provided.
  3. Regardless of whether we publish your story, we will add your name and e-mail address to the NeuroPace email list to hear from us about product updates, upcoming events and other relevant information. We will not sell your information to third parties. 
  4. Our use of your information is subject to our Privacy Policy, which you can access here.
neuropace logoLogo Header Menu
  • Patients
  • Providers
  • Corporate
  • Investors
  • nSight
  • PDMS
  • Take the Quiz
  • Clinical Trials